Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form agreeing to take part in the study
• People aged 18 or older
• People who have a confirmed diagnosis of multiple myeloma, based on standard international diagnostic guidelines
• People whose multiple myeloma can be measured through tests at the time of screening
• People who have already received at least 2 different treatment courses for multiple myeloma, including at least one from each of these three types: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 therapy
• People whose multiple myeloma has been confirmed to have gotten worse during or after their most recent treatment
• People whose multiple myeloma showed at least a partial response (some improvement) during at least one previous treatment
• People with a general health and activity level rated 0 to 2 on a standard medical scale (meaning people who are fully active, have some limitations but can care for themselves, or are up and about more than half of waking hours) (confirm with trial site)

Who may not be able to join:

• People who have previously been treated with drugs targeting BCMA or anti-CD3 therapies
• People who have used another experimental medicine or medical device within the past 30 days (or longer, depending on the specific drug), or who plan to use one during the study
• People who had their own stem cells transplanted within the past 12 weeks, or who have ever had a stem cell transplant from a donor
• People who are planning to have a stem cell transplant before their disease gets worse during the study
• People who have had another type of cancer within the past 5 years, with some exceptions for certain skin cancers, early-stage cervical or breast conditions, or other cancers the treating doctor considers fully treated with very low risk of return
• People with certain serious ongoing health conditions, including:
  • Severe chest pain or angina (class III–IV)
  • Unstable chest pain or a heart attack within the past 6 months
  • Severe heart failure (class III–IV)
  • Significant heart rhythm problems that have not responded to maximum treatment
  • Moderate to severe asthma, severe chronic lung disease, a history of serious allergic swelling (angioedema), or severe breathing problems
  • Active autoimmune disease (some exceptions apply — confirm with trial site)
  • An active infection in the past 14 days that required treatment
  • Any other serious health condition the treating doctor believes significantly raises safety risks
• People who have amyloidosis (a condition where abnormal proteins build up in organs)
• People who show signs that multiple myeloma has spread to the membranes around the brain or spinal cord
• People with HIV, active hepatitis B, or hepatitis C
• People who have had major surgery within the past 14 days, have not fully recovered from surgery, or are planning surgery during the study
• People who are pregnant, breastfeeding, planning to become pregnant, or planning to father a child during the study or within 180 days after the last dose of the study drug

Important: Always verify eligibility with the trial site directly before applying.